Isomorphic Labs
Malcolm Spain is a Senior Research Investigator and Senior Scientist at Isomorphic Labs since November 2022, focusing on advanced research in medicinal chemistry. Previously, Malcolm served as Senior Scientist I at Sosei Heptares, where expertise in structure-based drug design facilitated the development of small molecule clinical candidates targeting GPCRs. A dual background in synthetic medicinal chemistry was established at Vertex Pharmaceuticals, culminating in the synthesis of a notable pain treatment and receiving the Vertex Outstanding Contributor Award. Malcolm's academic roots include a PhD in Organic Chemistry from the University of Manchester and significant research contributions as a Postdoctoral Researcher at the University of Sydney, where mentorship of junior researchers was emphasized. Additional experience spans consulting roles and various positions in leading pharmaceutical companies, with numerous publications in esteemed journals reflecting a strong commitment to medicinal chemistry and drug discovery.
Isomorphic Labs
7 followers
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.